Related by context. All words. (Click for frequent words.) 72 VADT 60 Digital Mammographic Imaging 59 CARE HF 58 ASCEND HF 57 STRIDE PD 57 Carotid Revascularization Endarterectomy vs. 57 PROactive study 56 APPRAISE 56 carotid artery stenting CAS 56 Complications Trial 56 prospective nonrandomized 55 number NCT# ClinicalTrials.gov 55 spokesman Phil Budahn 55 BARI 2D 55 meta regression 55 trials RCTs 54 Intervention Effectiveness CATIE 54 prospective observational studies 54 double blinded randomized 54 chemoprevention trials 54 Clinical Antipsychotic Trials 54 Cholesterol Levels SPARCL 54 antithrombotic therapies 54 clevidipine 54 ThermoDox ® clinical 54 INTERHEART study 54 placebo controlled clinical 54 placebo controlled Phase III 54 Meta analyzes 54 Normative Aging Study 54 Screening Trial DMIST 53 retrospective cohort 53 prospective multicentre 53 CALGB 53 Diabetes ACCORD 53 thorough QT 53 PRIMO CABG 53 phase IIIb 53 substudy 53 randomized controlled trials RCTs 53 Randomized controlled 53 NATRECOR ® 53 randomized metastatic breast 53 kidney urologic 53 CINQUIL 53 Phase IIb III 53 atherothrombosis 52 thrombo embolic 52 proven VistA EHR 52 prospective multicenter study 52 ONTARGET 52 SCD HeFT 52 ExTRACT TIMI 52 IMPROVE HF 52 Lipid Lowering Treatment 52 Edge STudy 52 riociguat 52 conducted retrospective cohort 52 Intervention Trial 52 venous thromboembolic disease 52 postmarketing adverse 52 Intervention Trial GAIT 52 abnormal glucose tolerance 52 CYT# potent vascular disrupting 52 BOLDER II 52 SORT OUT III 52 phase IIb study 52 NATRECOR R 52 prelicensure 52 prospective longitudinal 52 longitudinal cohort 52 comorbid depression 52 bone density measurements 52 atherothrombotic disease 52 prospective randomized multicenter 51 meta analyzes 51 Val HeFT 51 carotid atherosclerosis 51 multicentre study 51 Aggressive Reduction 51 chronic myocardial ischemia 51 ACOSOG Z# 51 multicenter trials 51 HORIZONS AMI 51 skin sterol 51 Dialysis Outcomes 51 CURRENT OASIS 7 51 CIMZIA TM certolizumab pegol 51 nonrandomized 51 observational cohort 51 chromium supplementation 51 neuropsychiatric symptoms 51 Heavy snorers 51 ACRIN 51 Subgroup analyzes 51 EMPOWER ™ 51 deCODE AF TM 51 multicenter Phase II 51 allogeneic HSCT 51 HORIZONS AMI trial 51 retrospective cohort study 51 coinfected patients 51 NICE SUGAR 51 CHAMPION PCI 51 onset AF 51 GERD migraine headaches 51 ADVANCE PD 51 multicentre prospective 51 RCTs 51 untreated OSA 51 Prostate Lung Colorectal 51 RIO Lipids 51 UKPDS 51 Renal Cell Carcinoma RCC 51 ACCORD Lipid 51 EchoCRT 51 immunochemical fecal occult 51 β blockers 51 randomized controlled clinical trials 51 subgroup analyzes 51 longitudinal cohort study 50 HOPE TOO 50 Corus CAD 50 prospective observational 50 PFO migraine 50 pulmonary toxicity 50 CYP#D# inhibitor 50 TAXUS VI 50 NSQIP 50 metabonomics 50 randomized controlled clinical 50 methodological limitations 50 Teriflunomide 50 MGd 50 multicentre 50 PROactive Study 50 pharmacokinetic PK study 50 WHEL 50 #F FDG PET 50 CTRC AACR San Antonio 50 Phase IIIb study 50 Women Ischemia Syndrome 50 ADA Scientific Sessions 50 SIMPADICO 50 pathogenetic mechanisms 50 Wisconsin Sleep Cohort 50 underwent coronary angiography 50 Dr. Fehlings 50 thoracoscopic lobectomy 50 landmark ATHENA study 50 Outpatient Setting 50 serum phosphorous 50 placebo controlled studies 50 RSD# oral 50 prospective randomized placebo 50 carotid artery narrowing 50 postmenopausal hormone therapy 50 de Werf 50 CUSTOM III 50 MADIT II 50 WHIMS 50 intracranial stenosis 50 Epidemiologic studies 50 Primary endpoints 50 MTWA testing 50 ARBITER 6 50 Multiethnic Study 50 BCIRG 50 Marion VAMC 50 arrogantly compounded 50 Prostate AdenoCarcinoma Treatment 50 AVERROES 50 AACR San Antonio 50 biostatistical analysis 50 limiting generalizability 49 observational studies 49 HYVET 49 epidemiologic studies 49 ConclusionThis 49 PROSTVAC TM 49 PLCO trial 49 Secondary efficacy endpoints 49 EMBLEM TM 49 FFR measurements 49 STEP BD 49 confirmatory clinical 49 antiplatelet therapies 49 postoperative mortality 49 randomized controlled multicenter 49 HCV SPRINT 49 PLX STROKE targeting 49 Vertos II 49 comorbid conditions 49 Afatinib 49 PCWP 49 vascular endothelial dysfunction 49 nomograms 49 genomic biomarker 49 prostate carcinogenesis 49 PM#.# exposure 49 REACH Registry 49 SYNTAX 49 selenium supplementation 49 RE LY trial 49 metaanalysis 49 HF ACTION 49 FDG PET scans 49 multicenter clinical trials 49 multicenter prospective 49 RE LY ® 49 impaired insulin secretion 49 relapsed MM 49 meta analysis pooling 49 CaPSURE 49 RESOLUTE clinical 49 urothelial cancer 49 prostate cancer CaP 49 EMPOWER TM 49 preclinical efficacy 49 ongoing Phase IIIb 49 basal bolus regimen 49 obese postmenopausal 49 REVIVE Diabetes 49 prospectively stratified 49 NP2 Enkephalin 49 BoNTA 49 atherosclerotic renal artery stenosis 49 Systematic reviews 49 Singh Manoux 49 VAMCs 49 gallium nitrate 49 multicenter randomized clinical 49 neuropsychiatric events 49 ERIC CANTOR R 49 polyarticular 49 APEX AMI trial 49 observational cohort study 49 Proellex TM 49 REG1 49 MADIT CRT 49 OLYMPIA registry 49 PRESEPT 49 Combination antiretroviral therapy 49 Nissen meta analysis 49 SPARCL 49 stratifying patients 49 serum lipid 48 gynecologic procedures 48 GRECC 48 Coronary CTA 48 Amy Abernethy 48 exploratory endpoints 48 Genitourinary Cancers Symposium 48 torcetrapib atorvastatin 48 QTinno 48 Inflammatory diseases 48 psychiatric comorbidities 48 Observational studies 48 Multicenter AIDS 48 pharmacological therapies 48 Cardiotoxicity 48 laparoscopic bariatric surgery 48 urolithiasis 48 PRIMO CABG2 48 Demark Wahnefried 48 p# biomarker 48 Joel Kupersmith 48 bile acid metabolism 48 ToGA 48 FDG PET imaging 48 genetic polymorphisms 48 randomizing patients 48 cerebral microbleeds 48 PreCISe 48 blinded randomized controlled 48 transrectal ultrasound guided 48 oral anticoagulation 48 Avastin adjuvant 48 GEM OS2 48 MGN# 48 EDEMA3 trial 48 Heart Failure Clinic 48 PLCO 48 placebo controlled trials 48 pharmacogenetic tests 48 DMIST 48 paclitaxel eluting stents 48 tramiprosate Alzhemed TM 48 fidaxomicin Phase 3 48 Phase #b/#a 48 postmenopausal hormones 48 comorbid psychiatric disorders 48 MADIT CRT trial 48 management biostatistical analysis 48 papillary renal cell carcinoma 48 EEG abnormalities 48 circulating endothelial cells 48 randomized trials 48 inflammatory biomarkers 48 Zemplar Capsules 48 Phase IIIB IV 48 SYNTAX trial 48 TAXUS ARRIVE 48 angiographically 48 immunohistochemical 48 Posttraumatic Stress Disorder 48 EXPLORE Xa 48 BUMED 48 PARTNER Trial 48 GRNCM1 48 Prostate Cancer Prevention 48 biostatistical 48 Mayo Clinic oncologist 48 MERLIN TIMI 48 subanalysis 48 antiangiogenic therapy 48 CT angiograms 48 Chronic Disease Outcomes 48 Dr. Fonstein 48 blinded randomized placebo controlled 48 ALLHAT 48 ROCHESTER Minn. Mayo Clinic 48 coexisting illnesses 48 generalizability 48 pharmacogenetic testing 48 bazedoxifene conjugated estrogens 48 perinatal outcomes 48 arzoxifene 47 USUHS 47 ALK inhibitors 47 ECASS 47 extracolonic findings 47 CTEPH 47 Coronary angiography 47 randomized multicenter trial 47 antipsychotic prescribing 47 journal Arteriosclerosis Thrombosis 47 LHRH receptor positive 47 undergoing coronary angiography 47 placebo controlled dose escalation 47 atypical femur fractures 47 immunotherapeutic approaches 47 prospectively defined 47 unmeasured confounders 47 genomewide association studies 47 carotid revascularization 47 endothelin antagonists 47 Chlamydia trachomatis infection 47 thromboprophylaxis 47 Randomized clinical trials 47 liver transplant recipients 47 meta analysis 47 AIR2 Trial 47 Subgroup analysis 47 Clinicaltrials.gov 47 Dr. Cliby 47 multicenter placebo controlled 47 statin medications 47 Tumor Response 47 Molecular Genetic 47 NO# [002] 47 pharmacologic treatments 47 ACCORD Eye 47 Atherosclerosis MESA 47 MAGE A3 ASCI 47 BRCA testing 47 Vaccine Immunology 47 invasive lobular carcinoma 47 Xiao Ou Shu 47 preclinical pharmacokinetic 47 null responder HCV 47 AVADO 47 ABSORB trial 47 National Coverage Determination 47 sociodemographic characteristics 47 Study AREDS 47 ADMIRE HF 47 pharmacokinetic parameters 47 CAMMS# 47 pharmacologic stress 47 pivotal bioequivalence 47 postoperative radiotherapy 47 Asthma Intervention 47 Appropriateness Criteria 47 Polyp Prevention Trial 47 HIV HCV coinfected 47 antithrombotic therapy 47 nonrandomized studies 47 dietary interventions 47 SWOG 47 GPRD 47 biostatisticians 47 Methods Retrospective 47 transient elastography 47 randomized clinical trials 47 neratinib 47 Phase Ib IIa clinical 47 journal Pharmacotherapy 47 SYMMETRY trial 47 neurocognitive deficits 47 ICON7 47 antibiotic regimens 47 antiretroviral naïve 47 Tsimikas 47 thoracic aortic disease 47 randomized clinical 47 Zevalin consolidation 47 journal CHEST 47 carotid stenosis 47 nutrient supplementation 47 cardioembolic stroke 47 antiplatelet medications 47 prognostic markers 46 nocturnal hemodialysis 46 pulmonary artery catheterization 46 Dr. Kenneth Covinsky 46 Dr. Sosne 46 BRIM3 46 ASPIRE HIGHER 46 CT perfusion 46 chromium picolinate supplementation 46 pharmacoeconomic 46 GAMMAGARD 46 probiotic supplementation 46 VTE prophylaxis 46 STICH trial 46 renal denervation 46 Referenced EEG ® 46 methodological flaws 46 thromboembolic complications 46 MYTHOS trial 46 journal BJU International 46 Bruce Dohrenwend psychiatric 46 microbiologically evaluable 46 actigraphy 46 Tasigna prolongs 46 prospective observational cohort 46 silent ischemia 46 chemopreventive agents 46 Study ADCS 46 MDRF 46 endoscopic retrograde cholangiopancreatography ERCGrant Parpan 46 catheter ablations 46 tumor histology 46 Phase 2a clinical 46 SGAs 46 Molecular Cancer 46 transcranial Doppler ultrasound 46 subthreshold depression 46 nulliparous women 46 mechanistic studies 46 postoperative complication 46 Phase Ib clinical 46 Armed Forces Radiobiology Research 46 postapproval 46 postoperative chemotherapy 46 phase IIa clinical 46 fidaxomicin Phase 46 pharmacoeconomic analysis 46 Health Initiative WHI 46 Arteriosclerosis Thrombosis 46 antioxidant supplementation 46 retrospectively analyzed 46 VITAL Trial 46 methodologically rigorous 46 Congressionally Directed Medical 46 HER2 overexpression 46 VAOIG 46 denosumab oncology 46 intravenous bisphosphonates 46 Veterans Brain Injury 46 drug eluting stent implantation 46 poor metabolizers 46 Randomized trials 46 journal Anesthesia 46 arthrography 46 APOE genotype 46 randomized blinded 46 MDRD 46 bepotastine besilate nasal spray 46 prognostic variables 46 phase IIa 46 breast cancer recurrences 46 bolus dose 46 prognostic indicators 46 colorectal carcinogenesis 46 RRMS patients 46 REMINYL ® 46 perfusion MRI 46 multivariate analyzes 46 journal Ophthalmology 46 multicentric 46 HER2 positive cancers 46 strapless organza pleated gown 46 ADVEXIN therapy 46 etiologic factors 46 core needle biopsies 46 randomized controlled trials 46 eculizumab therapy 46 vitamin D inadequacy 46 topical NSAIDs 46 adjuvant therapies 46 PET CT scans 46 abnormal cytology 46 KRAS status 46 nodal metastasis 46 Alison Stuebe 46 pharmacokinetic pharmacodynamic 46 retrospective observational study 46 KRAS gene mutations 45 Laura Mauri 45 ACS NSQIP 45 susceptibility loci 45 Bruce Psaty 45 journal Anesthesiology 45 Prof. Gozes 45 lignan intake 45 Endocrine Practice 45 noncardiac chest pain 45 Rachel Ballard Barbash 45 intravenous dosing 45 Dr. Tashkin 45 proliferative retinopathy 45 molecular biomarker 45 OPT CHF 45 HCV antibody 45 nemesis Shinseki 45 randomized controlled trial 45 OPTIMIZE HF 45 NICE guideline 45 phase IIb trial 45 sonographic diagnosis 45 clinical pharmacology studies 45 methodological weaknesses 45 guideline concordant 45 non pharmacological interventions 45 Curt Furberg 45 PCI ExTRACT TIMI 45 psychopharmacological 45 causal pathways 45 familial clustering 45 cardiac perfusion 45 MDRD equation 45 journal Clinical Gastroenterology 45 Baseline characteristics 45 cognitive behavioral therapies 45 Neuroepidemiology 45 Sackner Bernstein 45 Digestive Diseases Week 45 Circulation Heart Failure 45 poststroke depression 45 OVA1 ® 45 dose proportionality 45 Robert Rosenheck 45 designated HVTN 45 Framingham Offspring Study 45 Health Initiative Observational 45 Yikyung Park 45 cardioprotective effects 45 Nalini Ranjit 45 Pre RELAX AHF 45 rALLy trial 45 clinicopathological 45 HyQ 45 Michael F. Leitzmann 45 electrophysiologic 45 Thorough QT 45 duplex ultrasonography 45 phase Ib 45 percutaneous cryoablation 45 coronary CTA 45 genotypic resistance 45 journal Neurorehabilitation 45 multimodality imaging 45 Paul Aisen 45 Coronary artery bypass grafting 45 opioid naive 45 journal Urology 45 Dr. Sharonne Hayes 45 VLER 45 pharmacodynamic markers 45 microalbumin 45 ultrastructural 45 pretransplant 45 TQT studies 45 International Neuropsychological Society 45 FDG-PET/CT 45 budesonide MMX Phase III 45 dosage regimens 45 dose escalation phase 45 hyperacute 45 GEM OS1 45 CLBP 45 USPSTF recommends 45 randomized controlled 45 procedural sedation 45 Accessed #/#/# [001] 45 pharmacodynamic PD 45 placebo controlled clinical trials 45 Wactawski Wende 45 cortical stimulation 45 dietary questionnaires 45 ICD therapy 45 GWTG 45 pharmacodynamic endpoints 45 swallowing disorders 45 vestibular rehabilitation 45 isoflavone supplement 45 cerebral angiography 45 Diabetologia 45 PECARN 45 OEF OIF veterans 45 demonstrated antitumor activity 45 hematopoietic cancers 45 CYP#D# genotype 45 pressure monitoring ABPM 45 SFVAMC 45 PDE# inhibitors 45 coxibs 45 Month Variance 45 Dr. Chodick 45 psychotherapeutic treatments 45 gene loci 45 histopathologic 45 cerebral oximetry 45 dose escalation Phase 45 James Cerhan MD 45 placebo controlled multicenter 45 thyroid nodules 45 OvaRex ® MAb 45 postmarketing surveillance 45 postexposure prophylaxis 45 Multivariate logistic regression 45 Karolinska Institute Stockholm 45 Dr. Montori 45 tipranavir ritonavir 45 Multivariable logistic regression 45 obstructive coronary artery 45 neurodevelopmental outcome 45 radiographic outcomes 45 poststroke 45 pathophysiologic mechanisms 45 toxicologic 45 symptomatic pulmonary embolism 45 magnesium intake 45 semistructured interviews 45 Sociodemographic 45 multicenter 45 nonpharmacologic 44 Histopathological 44 Surgeon General Lt. Gen. 44 dietary acrylamide 44 PREVENT IV 44 Clinical Gastroenterology 44 multiple logistic regression 44 Negative Symptoms 44 journal Atherosclerosis 44 NT proBNP assay 44 radiographic findings 44 Cochrane reviewers 44 NPWH 44 lipid lowering therapy 44 Aging USDA HNRCA 44 buprenorphine implants 44 visceral metastases 44 pretest probability 44 diagnostic prognostic 44 serum lipid levels 44 molecular biomarkers 44 Edward Giovannucci 44 Bresalier 44 Phase #/#a 44 diagnostic modality 44 immunosuppressant therapy 44 Phase Ib II 44 Radiology Imaging Network 44 PLoS ONE journal 44 journal Cephalalgia 44 nutritional epidemiology 44 genomewide 44 NeuroImage 44 Dr. Pasinetti 44 EuroSCORE 44 #q# deletion 44 scintigraphic 44 developmental neurotoxicity 44 KRAS variant 44 demonstrated clinically meaningful 44 haemodynamic 44 CRLX# 44 serum lipids 44 CoQ# supplementation 44 fundus photography 44 NHANES III 44 cardiopulmonary bypass surgery 44 prospective cohort 44 abnormal lipid 44 Ismail Beigi 44 genetic loci 44 Phase 2a clinical trials 44 clinicaltrials.gov 44 neuropathologic 44 residual confounding 44 transthoracic 44 DNA methylation markers 44 journal Hepatology 44 noscapine 44 VATS lobectomy 44 urine cytology 44 ICD implantation 44 pharmacodynamic parameters 44 Wendie Berg 44 psychosomatic medicine 44 Breast Cancer Symposium 44 iPrEx 44 eTag assays 44 predictive validity 44 ENDEAVOR clinical 44 univariate analyzes 44 medicine EBM 44 BETAS 44 Lipoic acid 44 tumor subtypes 44 beta1 integrin 44 clinicopathologic 44 Milbank Quarterly 44 multicenter phase 44 pharmacological interventions 44 perfusion CT 44 Simin Nikbin Meydani 44 esophagogastric 44 Dr. Roehrborn 44 Pharmacokinetic studies 44 serologic 44 colorectal neoplasia 44 Natural S equol 44 REPLACE Registry 44 etiologic 44 pathologic fractures 44 muscle biopsies 44 GBA mutations 44 endoscopist 44 pharmacological approaches 44 DSMB recommended 44 CombAT study 44 mammographic density 44 Multiple logistic regression 44 observational study 44 NEJM 44 HAART regimens 44 CLIRS 44 percutaneous vertebroplasty 44 viral kinetic 44 mammographically 44 immunohistochemical analysis 44 biopsychosocial 44 Roxana Mehran MD 44 trastuzumab emtansine T DM1 44 neurologic abnormalities 44 Swedish Mammography Cohort 44 arteriography 44 USPSTF recommendations 44 EGFR mutation status 44 therapeutic regimens 44 neurocognitive functioning 44 pharmacoepidemiology 44 VistA EHR 44 HNRCA 44 shorter telomere length 44 serum cotinine levels 44 multicenter study 44 Cytogenetic 44 hemodynamic measurements 44 methodologic 44 OvaRex MAb 44 EMBO Molecular Medicine 44 Symptom severity 44 ORACLE MS 44 ELCAP 44 prenatal exposures 44 Univariate 43 neurologic complications 43 acamprosate 43 journal Lancet Neurology 43 molecular determinants 43 clopidogrel pretreatment 43 ICD implantations 43 follicular adenoma 43 histopathologic diagnosis 43 coronary calcification 43 antiangiogenic agents 43 biochemical abnormalities 43 Norman Hollenberg 43 phase 2a 43 secretin 43 sonographic appearance 43 Univariate analysis 43 epidemiological studies 43 infantile colic 43 pharmacokinetic characteristics 43 NCIRE 43 Nonclinical 43 ENGAGE AF TIMI 43 neurocognitive function 43 androgen suppression 43 Toxicological Sciences 43 HPTN 43 & Analgesia retracted 43 genetic locus 43 Cochrane Database 43 Ashish K. Jha 43 olaparib 43 hypersensitivity allergic reactions 43 chest radiographs 43 Cardiovascular Intervention 43 flavopiridol 43 tracheal intubation 43 spirometric 43 histopathological examination 43 Commissioner Clark Dyrud 43 candidate DXL# CD# 43 spontaneous regression 43 physiologic responses 43 Cardiac catheterization 43 plasma pharmacokinetics 43 intravenous CK # 43 Tr DNA 43 mean ± SEM 43 Mermin oversees 43 pegnivacogin 43 vivo preclinical 43 undergo prostate biopsy 43 Nephrology Dialysis Transplantation 43 symptomatic DVT 43 CSF biomarkers 43 adverse cytogenetics 43 enzastaurin 43 DCE MRI 43 Cochrane Systematic Review 43 Multiethnic Cohort Study 43 Based Outpatient Clinics 43 OIF OEF veterans 43 InfoScriber 43 ELBW infants 43 postmarket surveillance 43 Chodick 43 APTIMA HPV 43 Comorbidity 43 hawthorn extract 43 PRESEPT study 43 Clinical Endocrinologists AACE 43 Elena Losina 43 multivariable analyzes 43 Ocular Hypertension Treatment 43 fusion enhancers 43 CaPre ™ 43 endoscopic examinations 43 atypical neuroleptics 43 radiographic examinations 43 pulmonary artery hypertension 43 Shkval developed 43 Phase III placebo controlled 43 abnormal Pap smear 43 CURE AF 43 Victor Montori MD 43 DEXA scans 43 confounder 43 Pharmacopeial Convention 43 immunopathology 43 familial aggregation 43 symptomatic paroxysmal AF 43 bioequivalency 43 retrospective observational 43 EORTC NCI 43 linear regression analyzes 43 avanafil PDE5 inhibitor 43 HIVNET 43 neurosensory 43 journal Circulation Cardiovascular 43 carotid bruit 43 HCAHPS survey 43 biomarker identification 43 pharmacodynamic properties 43 Evidence Therapeutic study 43 boron neutron capture 43 journal Epilepsia 43 epidemiologic 43 Dr. Boustani 43 Gaziano cardiologist 43 DeKosky 43 Shlipak 43 MR spectroscopy 43 hepatic lesions 43 mCare 43 carotid plaque 43 Professor Hardev Pandha 43 CLL8 43 Research Programs CDMRP 43 Phase IIA 43 Pseudomonas aeruginosa infections 43 intermittent dosing 43 BMD measurements 43 QTinno TM 43 Boston DbTechNo Results 43 psychiatric morbidity 43 serum markers 43 surrogate markers 43 journal Diabetologia 43 pharmacokinetics pharmacodynamics 43 pharmacodynamic effects 43 midstage clinical trials 43 cancer chemoprevention 43 diagnosing ADHD 43 Antioxidant supplements 43 Merikangas 43 placebo controlled 43 prognostic significance 43 dietary antioxidants 43 stem cell transplantations 43 NSDUH 43 BEXXAR Therapeutic Regimen 43 Tor Bjerkedal report 43 multivariate logistic regression 43 biologic DMARDs 43 renal biopsy 43 Logistic regression 42 XMRV virus 42 teratogenicity 42 Veterans Affairs VA 42 conjugated equine estrogen 42 Stacy Tessler Lindau 42 JoAnn Manson 42 unruptured aneurysm 42 journal Nature Reviews 42 HIV coinfected 42 genetic determinants 42 preoperative evaluation 42 CARDIA study 42 neurocognitive impairment 42 nonclinical studies 42 pathophysiological mechanisms 42 LibiGel Phase III 42 virological response 42 NHAMCS 42 PK PD modeling 42 anthropometric measurements 42 metabolic dysfunctions 42 transcranial Doppler 42 Acute renal failure 42 wrote Anders Sundstrom 42 PEARL SC 42 NovaVision VRT 42 clinical trial 42 ragweed allergic 42 DXA scan 42 NAMCS 42 Rosetta Genomics microRNA 42 scientifically invalid 42 chronic LBP 42 Towering scholar 42 neuropsychological assessments 42 convergent validity 42 Chevrolet Aveo U 42 PITX2 methylation 42 neuropsychological evaluations 42 neuro musculoskeletal 42 bivariate analyzes 42 micronutrient supplementation 42 proton MR spectroscopy 42 Phase 2b study 42 Clinical Endocrinology & 42 Tait Shanafelt MD 42 CANCER peer reviewed 42 National Trauma Databank 42 journal Resuscitation 42 Phase IIa trial 42 adenotonsillectomy 42 Hertzel Gerstein 42 oncological outcomes 42 conditional logistic regression 42 colonoscopic 42 ALISTA 42 Epidemiological studies 42 liver biopsies 42 postprocedure 42 unmeasured factors 42 bronchopulmonary dysplasia BPD 42 Serebruany 42 ExCell study 42 maternal fetal outcomes 42 enteroviral infection 42 postdischarge 42 biologic pathways 42 adenoidectomy 42 EMPHASIS HF trial 42 psychotherapeutic interventions 42 neurophysiologic 42 comorbid disorders 42 Veterans Illnesses